中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 11
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(11): 2478-2482

Value of age and D-dimer combined with Model for End-Stage Liver Disease in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2022.11.008
  • 1.

    Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

  • 2.

    School of Public Health, Zhengzhou University, Zhengzhou 450001, China

Research funding:

Sub-project of the National Science and Technology Major Project (2018ZX10302205-004)

More Information
  • Corresponding author: SUN Changyu, changyu8188@163.com(ORCID: 0000-0001-9993-8098)
  • Received Date: 2022-04-21
  • Accepted Date: 2022-05-25
  • Published Date: 2022-11-20
    Abstract
  •   Objective  To investigate the value of age and D-dimer (D-D) combined with Model for End-Stage Liver Disease (MELD) score in predicting the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF).  Methods  A total of 111 patients with HBV-ACLF who were hospitalized in The First Affiliated Hospital of Zhengzhou University from December 2019 to October 2021 were enrolled, and according to their prognosis on day 90 after confirmed diagnosis, they were divided into survival group with 49 patients and death group with 62 patients. Related clinical data were collected, including age, sex, underlying liver diseases, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), Albumin (Alb), D-D, prothrombin time (PT), plasma fibrinogen (FIB), prothrombin activity (PTA), international normalized ratio (INR), serum creatinine (SCr), and serum sodium (Na), and MELD score was calculated. Immunoturbidimetric assay was used to measure the plasma level of D-D. The t-test or the Mann-Whitney U test was used for comparison of continuous data between the two groups, and the chi-square test was used for comparison of categorical data between the two groups; a binary Logistic regression analysis was used to investigate the independent risk factors for the prognosis of patients, and the receiver operating characteristic (ROC) curve was used to predict the accuracy of variables.  Results  There were significant differences between the two groups in age, TBil, D-D, PT, PTA, INR, SCr, Na, and MELD score (all P < 0.05). The binary Logistic regression analysis showed that age (odds ratio [OR]=1.088, 95% confidence interval [CI]: 1.001-1.183, P=0.047), D-D (OR=1.521, 95%CI: 1.078-2.145, P=0.017), and MELD score (OR=1.892, 95%CI: 1.408-2.543, P < 0.001) were independent risk factors for the prognosis of HBV-ACLF patients. Age, MELD score and D-D had an area under the ROC curve (AUC) of 0.664, 0.869, and 0.887, respectively, in predicting the prognosis of HBV-ACLF, while D-D combined with age, age combined with MELD score, D-D combined with MELD score, and the combination of these three indicators had an AUC of 0.895, 0.906, 0.965, and 0.970, respectively. A combination of the three indices had a significantly increased AUC compared with other indices except D-D combined with MELD score. and the combination of these three indicators had relatively high sensitivity (0.935) and specificity (0.918).  Conclusion  Age, D-D, and MRLD score are independent risk factors for the prognosis of HBV-ACLF, among which D-D and MELD score have a good value in predicting prognosis, and the combination of these three indicators has a significantly better predictive value.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [2]
    BAJA JS, O'LEARY JG, LAI JC, et al. Acute-on-chronic liver failure clinical guidelines[J]. Am J Gastroenterol, 2022, 117(2): 225-252. DOI: 10.14309/ajg.0000000000001595.
    [3]
    SHANG DB, XIANG XG. Advances in the pathogenesis and treatment of acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(4): 765-769. DOI: 10.3969/j.issn.1001-5256.2021.04.005.

    尚大宝, 项晓刚. 慢加急性肝衰竭的发病机制和治疗进展[J]. 临床肝胆病杂志, 2021, 37(4): 765-769. DOI: 10.3969/j.issn.1001-5256.2021.04.005.
    [4]
    ZHANG TY, YU YP, XIA Q, et al. Research progress in liver transnlantation for acute-on-chronic liver failure[J]. Shanghai Jiaotong Univ (Medical Science), 2021, 41(2): 257-261. DOI: 10.3969/j.issn.1674-8115.2021.02.021.

    张天翼, 于也萍, 夏强, 等. 肝移植治疗慢加急性肝衰竭研究进展[J]. 上海交通大学学报(医学版), 2021, 41(2): 257-261. DOI: 10.3969/j.issn.1674-8115.2021.02.021.
    [5]
    FAN Q, LI Z. Liver transplantation for acute-on-chronic liver failure[J]. Ogran Transplant, 2022, 13(3): 333-337. DOI: 10.3969/j.issn.1674-7445.2022.03.008.

    范祺, 李照. 慢加急性肝衰竭的肝移植治疗[J]. 器官移植, 2022, 13(3): 333-337. DOI: 10.3969/j.issn.1674-7445.2022.03.008.
    [6]
    YUE HW, WANG YY. Change rule of blood coagulation, fibrinolysis and anti-coagulation indexes during the progress of chronic hepatitis B[J]. Lab Med Clin, 2020, 17(6): 755-757. DOI: 10.3969/j.issn.1672-9455.2020.06.010.

    乐华文, 王依屹. 凝血、纤溶和抗凝指标在慢性乙型肝炎病情进展中的变化规律[J]. 检验医学与临床, 2020, 17(6): 755-757. DOI: 10.3969/j.issn.1672-9455.2020.06.010.
    [7]
    YU B, PENG FE. The value of coagulation of the four combined with D-dimer detection in the severity of hepatitis B patients[J]. Chin J Thromb Hemostasis, 2021, 27(3): 431-432.

    于波, 彭粉娥. 凝血四项联合D二聚体水平检测在乙型肝炎患者严重程度的价值探讨[J]. 血栓与止血学, 2021, 27(3): 431-432.
    [8]
    QI T, ZHU C, LU G, et al. Elevated D-dimer is associated with increased 28-day mortality in acute-on-chronic liver failure in China: a retrospective study[J]. BMC Gastroenterol, 2019, 19(1): 20. DOI: 10.1186/s12876-019-0941-0.
    [9]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [10]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [11]
    XU Y, HUANG XP, CHEN L, et al. Role of coagulation abnormalities in thrombosis in patients with hepatitis B virus -associated acute -on -chronic liver failure[J]. J Clin Hepatol, 2021, 37(3): 560-564. DOI: 10.3969/j.issn.1001-5256.2021.03.012.

    徐英, 黄小平, 陈丽, 等. 凝血异常在HBV相关慢加急性肝衰竭患者血栓形成中的作用[J]. 临床肝胆病杂志, 2021, 37(3): 560-564. DOI: 10.3969/j.issn.1001-5256.2021.03.012.
    [12]
    ZHU LD, CAI LP, CHEN AZ, et al. Clinical significance of D-dimer and other fibrinolytic markers in chronic hepatitis[J]. Chin Health Stand Manage, 2021, 12(19): 94-97. DOI: 10.3969/j.issn.1674-9316.2021.19.031.

    朱李登, 蔡丽平, 陈爱灼, 等. D二聚体及其他纤溶指标在慢性肝炎的临床意义[J]. 中国卫生标准管理, 2021, 12(19): 94-97. DOI: 10.3969/j.issn.1674-9316.2021.19.031.
    [13]
    XU ZJ. Significance of FDP, antithrombin-Ⅲ and D-dimer levels in patients with chronic liver disease[J]. Contemp Med, 2021, 27(22): 9-10. DOI: 10.3969/j.issn.1009-4393.2021.22.004.

    许志坚. 慢性肝病患者FDP和抗凝血酶-Ⅲ以及D-二聚体水平检测的意义[J]. 当代医学, 2021, 27(22): 9-10. DOI: 10.3969/j.issn.1009-4393.2021.22.004.
    [14]
    LONG D, YU L, WU XL. A study of dynamic changes of plasma D- dimer and cytokine of patients with systemic inflammatory response syndrome[J]. Chongqing Med, 2012, 41(8): 738-740, 743. DOI: 10.3969/j.issn.1671-8348.2012.08.004.

    龙鼎, 喻莉, 武晓灵. 系统性炎症反应综合征患者血浆D-二聚体与细胞因子动态变化的研究[J]. 重庆医学, 2012, 41(8): 738-740, 743. DOI: 10.3969/j.issn.1671-8348.2012.08.004.
    [15]
    HERNAEZ R, SOLÀ E, MOREAU R, et al. Acute-on-chronic liver failure: an update[J]. Gut, 2017, 66(3): 541-553. DOI: 10.1136/gutjnl-2016-312670.
    [16]
    JIANG W, ZHENG ZM, LI J. Application of rapid determination of plasma D-dimer in liver disease changes and correlation of coagulation, fibrinolysis, and anticoagulation indexes in patients with chronic liver failure[J]. Lab Med Clin, 2019, 16(22): 3340-3343. DOI: 10.3969/j.issn.1672-9455.2019.22.032.

    蒋雯, 郑泽美, 李军. 凝血、纤溶与抗凝指标在慢性肝衰竭患者中的变化及相关性[J]. 检验医学与临床, 2019, 16(22): 3340-3343. DOI: 10.3969/j.issn.1672-9455.2019.22.032.
    [17]
    YU L, LONG D, WU XL, et al. The expression of uPA and uPAR in patients with systemic inflammatory response syndrome[J]. Chin J Emerg Med, 2011, 20(10): 1079-1083. DOI: 10.3760/cma.j.issn.1671-0282.2011.10.018.

    喻莉, 龙鼎, 武晓灵, 等. 全身炎症反应综合征中血浆尿激酶型纤溶酶原激活物及其受体的表达[J]. 中华急诊医学杂志, 2011, 20(10): 1079-1083. DOI: 10.3760/cma.j.issn.1671-0282.2011.10.018.
    [18]
    LIU YG, LI CS. Significance of lactic acid and D-dimer in patients with systemic inflammatory response syndrome[J]. Chin J Crit Care Med, 2003, 23(12): 851-852. DOI: 10.3969/j.issn.1002-1949.2003.12.012.

    刘禹赓, 李春盛. 血乳酸和D-二聚体测定在全身炎症反应综合征中的意义[J]. 中国急救医学, 2003, 23(12): 851-852. DOI: 10.3969/j.issn.1002-1949.2003.12.012.
    [19]
    ZHANG WJ, ZHAO LJ, WU JZ. Value of MELD、AARC、COSSH ccoring systems in evaluating the 90-day prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2020, 36(4): 813-817. DOI: 10.3969/j.issn.1001-5256.2020.04.021.

    张文佳, 赵丽娟, 吴基洲. MELD、AARC、COSSH评分系统对乙型肝炎相关慢加急性肝衰竭90天预后的评估价值[J]. 临床肝胆病杂志, 2020, 36(4): 813-817. DOI: 10.3969/j.issn.1001-5256.2020.04.021.
    [20]
    YANG S, LI XT, YANG L, et al. Research progress on prognostic models of acute-on-chronic liver failure associated with hepatitis B[J]. Int J Epidemiol Infect Dis, 2022, 49(1): 61-65. DOI: 10.3760/cma.j.cn331340-20210415-00076.

    杨烁, 李新婷, 杨兰, 等. 乙型肝炎相关慢加急性肝衰竭的预后模型[J]. 国际流行病学传染病学杂志, 2022, 49(1): 61-65. DOI: 10.3760/cma.j.cn331340-20210415-00076.
    [21]
    MING F, ZHANG Y, LI ZM, et al. Value of IL-33 and sST2 combined with MELD score in predicting short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Jiangsu Med J, 2022, 48(2): 186-190. DOI: 10.19460/j.cnki.0253-3685.2022.02.022.
    [22]
    LIN XF, LI LF, YU XY, et al. MELD-based models predict the prognosis of patients with acute-on-chronic hepatitis B liver failure[J/CD]. Chin J Clinician(Electronic Edition), 2012, 6(19): 5853-5857. DOI: 10.3877/cma.j.issn.1674-0785.2012.19.021.

    林贤丰, 李凌菲, 俞燮琰, 等. MELD相关评分体系对乙型肝炎相关慢加急性肝衰竭患者预后的预测价值[J/CD]. 中华临床医师杂志(电子版), 2012, 6(19): 5853-5857. DOI: 10.3877/cma.j.issn.1674-0785.2012.19.021.
    [23]
    TIAN XL, PENG Y, WU SL, et al. Liver failure staging and MELD predicted the short term prognosis of HBV-acute-on-chronic liver failure[J]. Chongqing Med, 2017, 46(8): 1079-1081. DOI: 10.3969/j.issn.1671-8348.2017.08.023.

    田小利, 彭颖, 吴松林, 等. 肝衰竭分期联合MELD评分对肝衰竭短期预后判断的研究[J]. 重庆医学, 2017, 46(8): 1079-1081. DOI: 10.3969/j.issn.1671-8348.2017.08.023.
    [24]
    ZHAO J, LI L, LI XH, et al. Value of a new predictive model in evaluating short-term prognosis of patients with hepatitis B virus related acute-on-chronic liver failure[J]. Chin Critical Care Med, 2020, 32(8): 988-993. DOI: 10.3760/cma.j.cn121430-20200102-00075.

    赵洁, 李力, 李秀惠, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者短期预后模型的建立及预测价值研究[J]. 中华危重病急救医学, 2020, 32(8): 988-993. DOI: 10.3760/cma.j.cn121430-20200102-00075.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (483) PDF downloads(74) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return